Metraipolis › archive › dc_ec07cb8ee1bb

Rethinking miRNAs in MSC-sEV therapeutics: implications for manufacture, mechanism of action, and development of robust potency CQAs — Europe PMC PMID:41551610

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41551610
DOI: 10.20517/evcna.2025.55
License (as archived): solo-consultazione
Archived: 2026-11-08T10:30:45.588Z
SHA-256 of the archived text: f18a92d94bd0b7b1f5c39b687865a1041b5163576503c3598e8cfe8b6944511d
Stable URL of this page: https://metraipolis.com/documento/dc_ec07cb8ee1bb

How to cite

Rethinking miRNAs in MSC-sEV therapeutics: implications for manufacture, mechanism of action, and development of robust potency CQAs — Europe PMC PMID:41551610 — Europe PMC (en), https://europepmc.org/article/MED/41551610 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ec07cb8ee1bb (Metraipolis archive dc_ec07cb8ee1bb, sha256 f18a92d94bd0b7b1f5c39b687865a1041b5163576503c3598e8cfe8b6944511d)

BibTeX

@misc{dcec07cb8ee1bb,
  title = {Rethinking miRNAs in MSC-sEV therapeutics: implications for manufacture, mechanism of action, and development of robust potency CQAs — Europe PMC PMID:41551610},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41551610},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ec07cb8ee1bb; sha256 f18a92d94bd0b7b1f5c39b687865a1041b5163576503c3598e8cfe8b6944511d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41551610. Agents can read the archived copy with the MCP tool read_document.